5-7 Multiple studies have linked gut dysbiosis a change or imbalance in the diversity, composition and functions of the microbiota to reduced GLP-1 levels
Fail 32 , 198202 (2010)
In five studies, background glucose-lowering treatment comprised metformin either as monotherapy or in combination with another oral medication
Sun YB, Zhao H, Mu DL, Zhang W, Cui J, Wu L, et al
Standard Research Assays Published GH secretagogue research commonly employs: Cultured pituitary somatotrope cell preparations with GH release measurement (ELISA in culture supernatant) cAMP accumulation assays measuring GHRHR-axis activation Intracellular calcium flux measurements (Fura-2 or similar) for GHS-R1a activation qPCR analysis of GHRHR and GHS-R1a expression in treated cultures Western blot for downstream signaling (PKA substrates, PLC phosphorylation) Rodent in-vivo preparations with serum GH and IGF-1 measurement by ELISA Receptor binding affinity studies with radiolabeled ligand displacement Time-resolved fluorescence resonance energy transfer (TR-FRET) for receptor-G-protein coupling analysis Phosphoproteomics of somatotrope signaling cascades following dual-agonist exposure Single-cell RNA-seq of pituitary cell populations following GH secretagogue exposure Whole-pituitary in-situ hybridization studies of receptor expression patterns Patch-clamp electrophysiology of somatotrope cell-membrane responses The kinetic profile of GH release in response to dual-receptor stimulation differs from single-receptor stimulation in published in-vivo research the combinatorial signal exhibits both a faster initial release component and a prolonged release phase, attributed to the different intracellular signaling timescales of the GHRHR (Gs-coupled, cAMP/PKA) and GHS-R1a (Gq-coupled, calcium-mediated) receptors
A double-blind randomized comparative study
